Center for Cancer and Blood Disorders
Oncology
Dr. Ralph V. Boccia, MD
|
|
Give Review
Ralph V. Boccia, MD works in the field of Oncology. He has 6 awards "CMS Meaningful Use Stage 1 Certification", "Top Doctors:Washington DC Area", "Top Doctors:Baltimore Area", "Top Doctors:Washington-Baltimore", "Top MD" and "Super Doctor". Ralph V. Boccia is a published doctor and has 40 publications published. The lastest was: 'Research on antibacterial and antifungal agents. XII--Synthesis and antimicrobial activity of some Mannich bases of diarylpyrroles.' Ralph V. Boccia, MD is registered with Medicare.
Publications
- Comparison of an extended-release formulation of granisetron (APF530) versus palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated wit...
- A phase 1/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple Myeloma.
- Efficacy and safety of IV ferumoxytol for adults with iron deficiency Anemia previously unresponsive to or unable to tolerate oral iron.
- Effects of enobosarm on muscle wasting and physical function in patients with Cancer: a double-blind, randomised controlled phase 2 trial.
- Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple Myeloma.
- Efficacy of oral palonosetron compared to intravenous palonosetron for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic...
- Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with Carcinoma of unknown primary site: a prospective ...
- A multicenter phase II study of darinaparsin in relapsed or refractory Hodgkin's and non-Hodgkin's Lymphoma.
- A modified regimen of pegylated liposomal doxorubicin, bortezomib and dexamethasone (DVD) is effective and well tolerated for previously untreated multiple Myeloma pat...
- A phase 2 randomized multicenter study of 2 extended dosing schedules of oral ezatiostat in low to intermediate-1 risk myelodysplastic Syndrome.
- Randomized phase III study of canfosfamide in combination with pegylated liposomal doxorubicin compared with pegylated liposomal doxorubicin alone in platinum-resistan...
- A phase II trial of FOLFOX6 and cetuximab in the first-line treatment of patients with metastatic colorectal Cancer.
- Phase 1-2a multicenter dose-ranging study of canfosfamide in combination with carboplatin and paclitaxel as first-line therapy for patients with advanced non-small cel...
- Zoledronic acid markedly improves bone mineral density for patients with monoclonal gammopathy of undetermined significance and bone loss.
- Utilization of darbepoetin alfa and epoetin alfa for chemotherapy-induced Anemia.
- Erythropoietic agents in chemotherapy-induced Anemia: a review of recent therapeutic progress, issues, and concerns.
- Assessment and management of cutaneous reactions with amifostine administration: findings of the ethyol (amifostine) cutaneous treatment advisory panel (ECTAP).
- Improved tolerability of amifostine with rapid infusion and optimal patient preparation.
- A dose-finding and safety study of novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia in patients receiving multicycle chemotherapy.
- Research on antibacterial and antifungal agents. XII--Synthesis and antimicrobial activity of some Mannich bases of diarylpyrroles.
- AMSA: a phase II trial in resistant and recurrent Acute myelogenous leukemia.
- A hemolytic-uremic Syndrome with the acquired immunodeficiency Syndrome.
- Prolonged survival in Acute myelogenous leukaemia without maintenance chemotherapy.
- Salmonella typhimurium enteritis and bacteremia in the acquired immunodeficiency Syndrome.
- Multiple recurrences of Acute tumor lysis syndrome in an indolent non-Hodgkin's lymphoma.
- Coexisting Hodgkin's Disease and mycosis fungoides. Immunohistochemical proof of its existence.
- The effectiveness of darbepoetin alfa administered every 3 weeks on hematologic outcomes and quality of life in older patients with chemotherapy-induced Anemia.
- Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple Myeloma: a prospective, multi...
- Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced Anemia: the 20030125 Study Group Trial.
- Darbepoetin alfa administered every three weeks is effective for the treatment of chemotherapy-induced Anemia.
- A multicenter randomized clinical trial evaluating interleukin-2 activated hematopoietic stem cell transplantation and post-transplant IL-2 for high risk breast Cancer...
- Darbepoetin alfa in anemia management: a vital role in Cancer care.
- Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi...
- Monoclonal gammopathy of undetermined significance: a consensus Statement.
- A phase II trial of panobinostat, a histone deacetylase inhibitor, in the treatment of patients with refractory metastatic renal cell Carcinoma.
- Results of a multicenter open-label randomized trial evaluating infusion duration of zoledronic acid in multiple Myeloma patients (the ZMAX trial).
- Romiplostim or standard of care in patients with Immune thrombocytopenia.
- Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple Myeloma.
- Randomized phase III trial of APF530 versus palonosetron in the prevention of chemotherapy-induced nausea and vomiting in a subset of patients with breast Cancer recei...
Procedures Preformed
- Plasmapheresis
- Thoracentesis
Conditions Treated
- Acute Leukemia
- Adrenal Gland Cancer
- Anemia
- Antiphospholipid Syndrome (APS)
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
- Top Doctors:Washington DC Area
- Top Doctors:Baltimore Area
- Top Doctors:Washington-Baltimore
- Top MD
- Super Doctor
Education
-
National Institutes of Health Clinical Center -
Universidad Autonoma de Guadalajara
Hospital
-
Sibley Memorial Hospital -
MedStar Georgetown University Hospital -
Holy Cross Hospital -
Suburban Hospital
Drug Facts
| NPI NUMBER | 1881663284 | |
| NPPES Provider LastName | BOCCIA | |
| NPPES Provider FirstName | RALPH | |
| NPPES Provider ZIPCode | 208171809 | |
| NPPES Provider State | MD | |
| Specialty Description | Hematology/Oncology | |
| Total Claim Count | 441.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 16.0 | |
| Percent Opioid Claims | 3.63 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1881663284 |
| Last Name Of The Provider | BOCCIA |
| First Name Of The Provider | RALPH |
| View All |
Similar Doctors
|
|
Dr. Kieron M. Dunleavy, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Henry C. Stevenson-Perez, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Edwarda M. Buda, MD |
|
|
Dr. Andre Larochelle, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Dickran G. Kazandjian, MD |
|
|
Dr. Christian S. Hinrichs, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. James L. Gulley, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Frederick A. Dorr, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Charles D. Bolan Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Ronald E. Gress, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Gregory A. Curt, MD
This Doctor is OpenDoctor Recommended.
This doctor has more publications
|
|
|
Dr. Michael D. Axelson, MD |
|
|
Dr. Alan B. Ney, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Irina G. Veytsman, MD
This Doctor is OpenDoctor Recommended.
|